Article
Oncology
Chao An, Mengxuan Zuo, Wang Li, Qifeng Chen, Peihong Wu
Summary: This study compared the effectiveness of hepatic arterial infusion chemotherapy (HAIC) and transarterial chemoembolization (TACE) in patients with infiltrative hepatocellular carcinoma (HCC) and found that HAIC significantly improved overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) compared to TACE. A nomogram model including various factors showed good predictive accuracy and outperformed other staging systems and conventional indices.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Shou-Wu Lee, Chieh-Ling Yen, Yu-Chi Cheng, Sheng Shun Yang, Teng-Yu Lee
Summary: Transcatheter arterial chemoembolization (TACE) is the recommended treatment for intermediate stage hepatocellular carcinoma (HCC). This study aimed to determine the radiological characteristics associated with prognosis in patients with intermediate stage HCC receiving TACE. The results showed that complete lipiodol retention, tumor feeding artery blockage, and no residual tumor blush were significant factors correlated with achieving objective response (OR) in TACE. Patients with OR had better overall survival than those without.
Review
Oncology
Zhiying Shao, Xin Liu, Chanjuan Peng, Liping Wang, Dong Xu
Summary: Combining portal vein embolization with transcatheter arterial chemoembolization may bring breakthroughs in treating hepatocellular carcinoma. Various studies have explored the feasibility, efficacy, long-term survival benefits, and potential side effects of this combined treatment approach.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Plant Sciences
He Zhu, Si-Yu Wang, Jin-Hao Zhu, Hui Liu, Ming Kong, Qian Mao, Wei Zhang, Song-Lin Li
Summary: The study showed that combining ginsenosides can continuously improve the efficacy and safety of TACE in the treatment of HCC, with Rg3 being the preferred choice for combination therapy.
Review
Biotechnology & Applied Microbiology
Gang Yuan, Zhiyin Liu, Weiming Wang, Mengnan Liu, Yanneng Xu, Wei Hu, Yao Fan, Xun Zhang, Yong Liu, Guangyan Si
Summary: Hepatocellular carcinoma (HCC) is a major global health concern with high incidence and mortality rates. Transarterial chemoembolization (TACE) is commonly used for the treatment of unresectable HCC, but its therapeutic effect is often limited. Recent research has focused on using nanomaterials as a drug delivery platform to improve the distribution and bioavailability of drugs in tumor tissues. Functionalized nanomaterials have been developed for targeted embolization, controlled drug release, and real-time imaging, aiming to enhance the therapeutic effect of TACE against HCC.
JOURNAL OF NANOBIOTECHNOLOGY
(2023)
Article
Gastroenterology & Hepatology
Xuhua Duan, Hao Li, Donglin Kuang, Pengfei Chen, Kai Zhang, Yanliang Li, Xiang He, Cheng Xing, Haibo Wang, Yaoxian Liu, Limin Xie, Shixi Zhang, Qiang Zhang, Peixin Zhu, Honglin Dong, Jichen Xie, Hui Li, Yong Wang, Ming Shi, Guangbin Jiang, Yandong Xu, Shiqi Zhou, Chunyu Shang, Jianzhuang Ren, Xinwei Han
Summary: The study evaluated the role of TACE plus apatinib (TACE + A) and TACE combined with apatinib plus camrelizumab (TACE + AC) in patients with unresectable hepatocellular carcinoma (HCC). The results showed that the TACE + AC group had better overall survival, progression-free survival, objective response rate, and disease control rate compared to the TACE + A group.
HEPATOLOGY INTERNATIONAL
(2023)
Article
Engineering, Biomedical
Zhiying Zheng, Mingxi Ma, Xiuping Han, Xiao Li, Jinxin Huang, Yuetong Zhao, Hanyuan Liu, Junwei Kang, Xiangyi Kong, Guoqiang Sun, Guangshun Sun, Jie Kong, Weiwei Tang, Guoqiang Shao, Fei Xiong, Jinhua Song
Summary: Conventional TACE formulations suffer from inadequate drug concentrations in HCC due to rapid dissociation of the emulsion. To address this, researchers developed biodegradable microspheres called BILMs loaded with IDA-MS. TACE with IDA-MS demonstrated significant tumor shrinkage and fewer adverse events compared to the IDA group. Additionally, TACE with IDA-MS enhanced the sensitivity of anti-PD1 immunotherapy, improved CD8+ T cell expression, and activated the tumor immune microenvironment in HCC. This study introduces a new approach for TACE therapy and immunotherapy, highlighting the future of HCC treatment.
ACTA BIOMATERIALIA
(2023)
Article
Oncology
Ali Mo, Qiao Zhang, Feng Xia, Zhiyuan Huang, Shasha Peng, Wenjing Cao, Hongliang Mei, Li Ren, Yang Su, Hengyi Gao, Weiqiang Chen
Summary: Preoperative TACE is found to be effective in improving the recurrence-free survival and overall survival for patients with solitary HCC (>= 10 cm) compared to those without preoperative TACE.
Article
Oncology
Dong Il Gwon, Gun Ha Kim, Hee Ho Chu, Jin Hyoung Kim, Gi-Young Ko, Hyun-Ki Yoon
Summary: The aim of this study was to determine the local recurrence rate in HCC patients who achieved a radiological complete response after B-TACE and identify factors associated with recurrence. The study found that subsegmental B-TACE had a high initial complete response rate and low recurrence rate. Oily subsegmentectomy can be considered as an index of successful treatment. Age and tumor location were independent predictive factors for recurrence.
Article
Radiology, Nuclear Medicine & Medical Imaging
Chung Man Moon, Yun Young Lee, Seul Kee Kim, Yong Yeon Jeong, Suk Hee Heo, Sang Soo Shin
Summary: 4D flow MRI can be used to predict treatment responses after TACE in cirrhotic patients with HCC. Flow parameters in PV and SV were significantly reduced in HCC patients before TACE and those with incomplete response after TACE, compared to patients without HCC. The average through-plane velocity and peak velocity magnitude in PV were independently associated with complete response after TACE.
Article
Radiology, Nuclear Medicine & Medical Imaging
Jimi Huh, Bohyun Kim, Jei Hee Lee, Je Hwan Won, Jinoo Kim, Yohan Kwon, Jai Keun Kim
Summary: Adding arterial subtraction images to LI-RADS v2018 LR-TR categorization in patients treated with TACE for HCC significantly increases the sensitivity for detecting viable tumors without compromising specificity and improves diagnostic confidence.
INVESTIGATIVE RADIOLOGY
(2021)
Article
Oncology
Kai-Cai Liu, Wei-Fu Lv, Dong Lu, Chang-Long Hou, Jun Xie, Yu-He Lu, Qi-Sheng Cao, Yu-Lin Tan, Ying-Zhan Zhang, Jie Liu
Summary: DEB-TACE treatment shows potential efficacy and safety in patients with HCC refractory to TACE, making it a promising option after the failure of conventional treatment. Further studies are needed to confirm its efficacy.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Medicine, Research & Experimental
Jiaren Mao, Zhongjun Tan, Xiaoqi Pan, Feijian Meng
Summary: TACE induces ischemia-hypoxia and local chemotherapy-induced cytotoxicity, but some patients do not respond. ASPP2 self-regulation may promote cell survival under hypoxic conditions and chemotherapy resistance. Lower ASPP1 expression and higher Beclin-1 expression were seen in patients who experienced HCC recurrence following TACE. ASPP2 expression in cancer tissue following TACE is an independent risk factor for HCC recurrence and overall survival.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2021)
Article
Engineering, Biomedical
Heegon Kim, Bongseo Choi, Samdeep K. Mouli, Hyunjun Choi, Kathleen R. Harris, Laura M. Kulik, Robert J. Lewandowski, Dong-Hyun Kim
Summary: This article presents a practical strategy for enhancing immune activation in transcatheter arterial chemoembolization (TACE) of hepatocellular carcinoma (HCC). The study demonstrates the safe and effective delivery of therapeutic agents using Pluronic F127 (PF127) incorporated with Lipiodol (LPD) during transcatheter intra-arterial (IA) local delivery. The combination of TACE and local delivery of immune adjuvant (TLR9 agonist CpG oligodeoxynucleotide) in transcatheter arterial chemo-immuno-embolization (TACIE) shows promising results in improving tumor regression and systemic anti-tumor immunity in HCC models.
ADVANCED HEALTHCARE MATERIALS
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Hui Chen, Gang Nan, Ding Wei, Ren-You Zhai, Ming Huang, Wu-Wei Yang, Bao-Cai Xing, Xu Zhu, Hai-Feng Xu, Xiao-Dong Wang, Xiao-Yong Zhang, Bao-Rang Zhu, Peng Liu, Guang Cao, Song Gao, Chun-Yi Hao, Ren-Jie Yang, Jian-Hai Guo, Xin Zhang, Kun Gao, Kun Wang, Jian-Feng Wang, Zi-Yu Li, Lin-Zhong Zhu, Rong Ding, Jing Li, Ling Zhao, Yu-Jun Shao, Hai-Chun Liu, Jie-Lai Xia, Ling Wang, Ling-Min Kong, Zhi-Nan Chen, Huijie Bian
Summary: In the adjuvant treatment of unresectable hepatocellular carcinoma, the combination of TACE and I-131-MabThera showed superior antirecurrence efficacy, significantly improved 5-year survival rate of patients, and was well tolerated.
JOURNAL OF NUCLEAR MEDICINE
(2022)